MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

bispecific T-cell engager

  • Home
  • bispecific T-cell engager
Leveraging Functional Immune Profiling to Predict Response in Myeloma Immunotherapy
Posted inHematology-Oncology news

Leveraging Functional Immune Profiling to Predict Response in Myeloma Immunotherapy

Posted by By MedXY 09/18/2026
This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.
Read More
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
Posted inDiabetes & Endocrinology news Oncology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

Posted by By MedXY 06/10/2026
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Modulating Coronary Artery Calcification Progression: Insights from the DANCODE Trial on Vitamin K2 and D3 Supplementation
  • Evaluating the Global Track Concept in Anterior Shoulder Instability with Glenohumeral Bone Loss: Implications for Clinical Decision-Making
  • Evaluating Rehabilitation Outcomes: Inpatient Rehabilitation Facilities Versus Skilled Nursing Facilities Post-Acute Stroke
  • Oral Irrigation Enhances Microbiome Stability and Recovery After Oral Cancer Reconstruction
  • Divarasib Compared with Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC: A Comprehensive Clinical and Translational Review
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top